<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Document</title>

<style>
body {
  font-family: "Avenir Next", Helvetica, Arial, sans-serif;
  padding: 1em;
  margin: auto;
  max-width: 42em;
  background: #fefefe;
}

h1,
h2,
h3,
h4,
h5,
h6 {
  font-weight: bold;
}

h1 {
  color: #000000;
  font-size: 28pt;
}

h2 {
  border-bottom: 1px solid #cccccc;
  color: #000000;
  font-size: 24px;
}

h3 {
  font-size: 18px;
}

h4 {
  font-size: 16px;
}

h5 {
  font-size: 14px;
}

h6 {
  color: #777777;
  background-color: inherit;
  font-size: 14px;
}

hr {
  height: 0.2em;
  border: 0;
  color: #cccccc;
  background-color: #cccccc;
}

p,
blockquote,
ul,
ol,
dl,
li,
table,
pre {
  margin: 15px 0;
}

img {
  max-width: 100%;
}

table {
  border-collapse: collapse;
  width: 100%;
}

table,
th,
td {
  border: 1px solid #eaeaea;

  border-radius: 3px;
  padding: 5px;
}

tr:nth-child(even) {
  background-color: #f8f8f8;
}

a,
a:visited {
  color: #4183c4;
  background-color: inherit;
  text-decoration: none;
}

#message {
  border-radius: 6px;
  border: 1px solid #ccc;
  display: block;
  width: 100%;
  height: 60px;
  margin: 6px 0px;
}

button,
#ws {
  font-size: 10pt;
  padding: 4px 6px;
  border-radius: 5px;
  border: 1px solid #bbb;
  background-color: #eee;
}

code,
pre,
#ws,
#message {
  font-family: Monaco, monospace;
  font-size: 10pt;
  border-radius: 3px;
  background-color: #f8f8f8;
  color: inherit;
}

code {
  border: 1px solid #eaeaea;
  margin: 0 2px;
  padding: 0 5px;
}

pre {
  border: 1px solid #cccccc;
  overflow: auto;
  padding: 4px 8px;
}

pre > code {
  border: 0;
  margin: 0;
  padding: 0;
}

#ws {
  background-color: #f8f8f8;
}

.send {
  color: #77bb77;
}
.server {
  color: #7799bb;
}
.error {
  color: #aa0000;
}
</style>


     </head>
  <body><p>This passage discusses the fundamental concept behind a
<strong>protective value study</strong>, which is an evaluation used in
underwriting (typically in insurance) to determine whether a particular
underwriting procedure is economically justified. The core idea is
straightforward: a procedure is considered valuable if the cost of
implementing it is <strong>less than the savings</strong> it generates
by reducing mortality (for life insurance) or morbidity (for health
insurance).</p>
<h3 id="key-points">Key Points:</h3>
<ol type="1">
<li><strong>Economic Justification</strong>: The underwriting procedure
must save more money (via reduced mortality/morbidity) than it costs to
implement.</li>
<li><strong>Core Question</strong>: “Will I save more than I spend?”
This is the essence of protective value analysis.</li>
<li><strong>Challenges</strong>: While the question is simple,
determining the answer is often complex due to the methods
involved.</li>
<li><strong>Purpose of the Paper</strong>: To introduce a <strong>simple
and general model</strong> that can be used to conduct protective value
studies.</li>
<li><strong>Use of Hypothetical Data</strong>: The paper does not
validate any particular underwriting process but rather demonstrates the
principles using reasonable but hypothetical data.</li>
</ol>
<h3 id="summary">Summary:</h3>
<p>The passage sets the stage for a study on evaluating the economic
benefits of underwriting procedures. It emphasizes that while the
principle of comparing costs and savings is straightforward, the
methodology can be complicated. The paper aims to simplify this process
by providing a general model and using hypothetical data to illustrate
its application.</p>
<h3 id="summary-explanation"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains how <strong>insurance pricing</strong> and
<strong>underwriting procedures</strong> are connected to risk
assessment.</p>
<ol type="1">
<li><p><strong>Standard vs. Substandard Risk</strong>:</p>
<ul>
<li>Insurance prices are set based on an assumed “standard” level of
<strong>mortality (for life insurance) or morbidity (for health
insurance)</strong>.</li>
<li>If an applicant has a higher risk than the standard level, they
should ideally be charged more or denied coverage.</li>
</ul></li>
<li><p><strong>Purpose of Underwriting Procedures</strong>:</p>
<ul>
<li>An underwriting procedure is valuable if it can identify applicants
with <strong>higher-than-standard risk</strong> (substandard risk).</li>
<li>Without such a procedure, insurers would mistakenly charge
<strong>standard rates</strong> to <strong>higher-risk
individuals</strong>, leading to financial losses.</li>
</ul></li>
<li><p><strong>Key to Protective Value</strong>:</p>
<ul>
<li>The <strong>effectiveness of an underwriting procedure</strong>
depends on how well it detects excess mortality/morbidity.</li>
<li>The better the procedure is at identifying high-risk individuals,
the <strong>greater the financial savings</strong> for the insurer.</li>
</ul></li>
</ol>
<h3 id="takeaway"><strong>Takeaway</strong>:</h3>
<p>The protective value of an underwriting procedure is determined by
its ability to <strong>prevent insurers from underpricing high-risk
individuals</strong>. If a procedure can accurately detect those with
above-average mortality/morbidity, it helps insurers charge
appropriately, leading to financial savings.</p>
<h3 id="summary-explanation-1"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains how <strong>excess mortality/morbidity
(M/M)</strong> is measured in underwriting and how different
underwriting decisions impact this measurement.</p>
<h3 id="key-points-1"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Measuring Excess Mortality/Morbidity</strong>:</p>
<ul>
<li>The <strong>most common method</strong> is to express
<strong>substandard M/M</strong> as a percentage of <strong>standard
M/M</strong> (e.g., 150% means 50% higher risk than standard).</li>
<li>This method aligns with <strong>reinsurance manuals</strong>, which
insurers refer to when assessing medical impairments.</li>
</ul></li>
<li><p><strong>Handling Special Cases</strong>:</p>
<ul>
<li><strong>Declined Applications</strong>: When an applicant is
declined, their M/M may be estimated as <strong>the maximum rating an
insurer would issue + 50% extra</strong>.</li>
<li><strong>Not Taken Applications (Not Takens)</strong>:
<ul>
<li>If the applicant was <strong>offered standard coverage but
declined</strong>, they are assumed to have <strong>standard
M/M</strong>.</li>
<li>If the applicant was <strong>offered substandard coverage but
declined</strong>, they are assumed to have <strong>substandard
M/M</strong>.</li>
</ul></li>
<li><strong>Exclusions &amp; Plan Modifications</strong>:
<ul>
<li>When an insurer modifies the coverage (e.g., excluding a condition),
it’s trickier to assess M/M.</li>
<li>If no substandard rating is given alongside the exclusion, it might
be reasonable to assume <strong>the exclusion equals the highest
acceptable substandard rating</strong>.</li>
</ul></li>
</ul></li>
</ol>
<h3 id="takeaway-1"><strong>Takeaway</strong>:</h3>
<p>Excess M/M is usually measured as a percentage above the standard
level. Special cases like declined policies, not-taken offers, and
exclusions require adjustments to accurately estimate excess risk. The
goal is to ensure fair pricing and accurate risk assessment in
underwriting.</p>
<h3 id="summary-explanation-2"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage discusses how to handle cases where <strong>direct
excess mortality/morbidity (M/M) data is unavailable</strong> for
certain medical impairments.</p>
<h3 id="key-points-2"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Lack of Direct Data</strong>:</p>
<ul>
<li>Some impairments may not have readily available excess M/M
information.</li>
<li>In such cases, insurers need to find alternative data sources and
compare them to a “standard” M/M level.</li>
</ul></li>
<li><p><strong>Using Standard Mortality/Morbidity Tables</strong>:</p>
<ul>
<li>The <strong>Society of Actuaries (SOA) 1975-80 Basic Mortality
Table</strong> is an example of a commonly used reference.</li>
<li>By making <strong>simple adjustments</strong> to such standard
tables, insurers can approximate the actual risk based on available
clinical data.</li>
</ul></li>
</ol>
<h3 id="takeaway-2"><strong>Takeaway</strong>:</h3>
<p>When specific excess M/M data isn’t available, insurers rely on
<strong>recognized mortality/morbidity tables</strong> and modify them
to estimate risk. This approach helps maintain consistency and accuracy
in underwriting decisions.</p>
<h3 id="summary-explanation-3"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage highlights the role of <strong>persistency</strong> (the
percentage of policyholders who keep their insurance policies over time)
in evaluating the <strong>savings impact</strong> of an underwriting
procedure.</p>
<h3 id="key-points-3"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Definition of Persistency</strong>:</p>
<ul>
<li><strong>High persistency</strong> means <strong>low lapse
rates</strong> (fewer policyholders canceling their policies).</li>
<li><strong>Low persistency</strong> means <strong>high lapse
rates</strong> (more policyholders dropping their coverage).</li>
</ul></li>
<li><p><strong>Impact on Excess Mortality/Morbidity (M/M)</strong>:</p>
<ul>
<li>When <strong>persistency is high</strong>, more policyholders
<strong>continue coverage</strong> for a longer time.</li>
<li>This increases the number of insured individuals, leading to a
<strong>higher total excess M/M</strong> (because more people remain
covered, including higher-risk individuals).</li>
</ul></li>
<li><p><strong>Relevance to Savings</strong>:</p>
<ul>
<li>Since underwriting procedures aim to <strong>detect and price risk
correctly</strong>, persistency affects the <strong>long-term cost
savings</strong> of these procedures.</li>
<li>If more high-risk individuals stay insured, the importance of
accurately assessing their risk <strong>increases</strong>.</li>
</ul></li>
</ol>
<h3 id="takeaway-3"><strong>Takeaway</strong>:</h3>
<p>Persistency directly influences the effectiveness of underwriting.
When more policyholders keep their policies for longer, the
<strong>cumulative impact of excess mortality/morbidity grows</strong>,
making accurate risk assessment even more critical for maximizing
<strong>savings</strong>.</p>
<h3 id="summary-explanation-4"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage discusses a second reason why
<strong>persistency</strong> is important, particularly for
<strong>substandard</strong> policyholders.</p>
<h3 id="key-points-4"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Substandard Policyholders Have Fewer
Options</strong>:</p>
<ul>
<li>People with <strong>higher health risks</strong> (substandard
insureds) often <strong>accept substandard coverage</strong> only
because they have <strong>no better alternative</strong>.</li>
<li>Unlike standard insureds, they <strong>cannot easily switch to a
cheaper or better policy</strong> elsewhere.</li>
</ul></li>
<li><p><strong>Higher Persistency Among Substandard
Policyholders</strong>:</p>
<ul>
<li>Because they lack alternative options, substandard policyholders
tend to <strong>keep their policies longer</strong> than standard
insureds.</li>
<li>This leads to <strong>higher persistency</strong> in the substandard
risk group.</li>
</ul></li>
<li><p><strong>Why Substandard Policyholders Avoid Lapsing</strong>:</p>
<ul>
<li>If a <strong>substandard insured voluntarily cancels (lapses) their
policy</strong>, they often know that:
<ul>
<li>They might not <strong>qualify for new coverage</strong> anywhere
else.</li>
<li>If they do qualify, it may be <strong>even more expensive</strong>
than their current policy.</li>
</ul></li>
</ul></li>
</ol>
<h3 id="takeaway-4"><strong>Takeaway</strong>:</h3>
<p>Persistency is especially high among <strong>substandard
insureds</strong> because they have limited alternatives. They are
<strong>less likely to cancel</strong> their policies, knowing that
obtaining new coverage could be difficult or impossible. This makes
<strong>accurate risk assessment even more critical</strong> for
insurers, as substandard policyholders are likely to stay on the books
longer.</p>
<h3 id="summary-explanation-5"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains the importance of the <strong>interest
rate</strong> when evaluating the savings from an underwriting
procedure.</p>
<h3 id="key-points-5"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Excess Mortality/Morbidity (M/M) Occurs Over
Time</strong>:</p>
<ul>
<li>The <strong>financial impact of excess M/M is spread over many
years</strong>, potentially for the entire life of an insurance
contract.</li>
<li>To properly assess the <strong>value of an underwriting
procedure</strong>, insurers must <strong>convert future excess M/M
savings into present value</strong>.</li>
</ul></li>
<li><p><strong>Present Value Calculation</strong>:</p>
<ul>
<li>Since costs (such as the expense of an underwriting procedure) occur
<strong>immediately</strong>, while the savings (from avoided excess
M/M) occur <strong>gradually</strong>, a <strong>present value
comparison</strong> is needed.</li>
<li>This allows insurers to directly compare <strong>the up-front cost
of underwriting vs. the long-term savings</strong>.</li>
</ul></li>
<li><p><strong>Impact of Interest Rate</strong>:</p>
<ul>
<li>The <strong>chosen interest rate</strong> reflects the insurer’s
<strong>time-value of money</strong> (i.e., how much they value money
now versus later).</li>
<li><strong>Higher interest rates</strong> → <strong>Lower present
value</strong> of excess M/M savings (because future savings are
discounted more).</li>
<li><strong>Lower interest rates</strong> → <strong>Higher present
value</strong> of excess M/M savings (because future savings are
discounted less).</li>
</ul></li>
</ol>
<h3 id="takeaway-5"><strong>Takeaway</strong>:</h3>
<p>Since underwriting savings happen over time, insurers
<strong>discount future savings to present value</strong> using an
interest rate. The <strong>higher</strong> the rate, the
<strong>lower</strong> the present value of future savings, meaning the
underwriting procedure might appear <strong>less beneficial</strong>.
The chosen rate should reflect the insurer’s financial outlook and
time-value preferences.</p>
<h3 id="summary-explanation-6"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains how the <strong>time period</strong> over which
excess mortality/morbidity (M/M) is measured affects its <strong>present
value</strong> and the overall savings evaluation of an underwriting
procedure.</p>
<h3 id="key-points-6"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Longer Time Period = Higher Present Value of Excess
M/M</strong>:</p>
<ul>
<li>The longer the time frame used to measure excess M/M, the
<strong>greater the total impact</strong>.</li>
<li>This happens because:
<ul>
<li>More years of <strong>excess M/M</strong> are included in the
calculation.</li>
<li>Excess M/M tends to <strong>increase with age</strong> (as insured
individuals grow older, their risk of mortality or morbidity
rises).</li>
</ul></li>
</ul></li>
<li><p><strong>Shorter Time Period Leads to Conservative
Estimates</strong>:</p>
<ul>
<li>If the time period chosen for measurement is <strong>shorter than
the maximum possible contract duration</strong>, the <strong>present
value of excess M/M will be underestimated</strong>.</li>
<li>This means the <strong>savings impact of the underwriting procedure
might appear smaller than it actually is</strong>.</li>
</ul></li>
</ol>
<h3 id="takeaway-6"><strong>Takeaway</strong>:</h3>
<p>The <strong>longer the time period</strong>, the
<strong>higher</strong> the present value of excess M/M due to
<strong>cumulative risk and aging effects</strong>. If the time frame is
<strong>too short</strong>, insurers may <strong>undervalue</strong> the
long-term benefits of an underwriting procedure, leading to a
conservative estimate of its financial impact.</p>
<h3 id="summary-explanation-7"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains how <strong>prevalence</strong> (the proportion
of the insured population that actually has excess mortality/morbidity
(M/M)) affects the overall savings from an underwriting procedure.</p>
<h3 id="key-points-7"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Accuracy Alone Isn’t Enough</strong>:</p>
<ul>
<li>Even if an underwriting procedure is <strong>perfectly
accurate</strong> (no false positives or false negatives), its overall
financial impact depends on <strong>how common excess M/M is</strong> in
the insured population.</li>
<li>If very few people have excess M/M, even a perfect test won’t lead
to significant savings.</li>
</ul></li>
<li><p><strong>The Role of Prevalence</strong>:</p>
<ul>
<li>The <strong>true proportion of people with excess M/M</strong>
influences the value of an underwriting procedure.</li>
<li>If <strong>prevalence is high</strong>, identifying excess M/M can
lead to <strong>substantial savings</strong>.</li>
<li>If <strong>prevalence is low</strong>, the potential for savings is
smaller, <strong>even if the procedure works perfectly</strong>.</li>
</ul></li>
<li><p><strong>Impact on Underwriting Strategy</strong>:</p>
<ul>
<li>When prevalence is <strong>high</strong>, stricter underwriting
procedures may be more justified.</li>
<li>When prevalence is <strong>low</strong>, costly or invasive
procedures may <strong>not be worth the expense</strong>.</li>
</ul></li>
</ol>
<h3 id="takeaway-7"><strong>Takeaway</strong>:</h3>
<p>Even a <strong>perfect underwriting procedure</strong> will only
generate meaningful savings if <strong>a significant portion of the
insured population actually has excess M/M</strong>. Understanding
<strong>prevalence</strong> helps insurers decide <strong>which
procedures are worth using</strong> based on their potential financial
impact.</p>
<h3 id="summary-explanation-8"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage expands on how <strong>prevalence</strong> (the
proportion of people with excess mortality/morbidity) affects
underwriting decisions and the use of medical testing.</p>
<h3 id="key-points-8"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Low Overall Prevalence → Selective Testing</strong>:</p>
<ul>
<li>If <strong>few applicants</strong> actually have excess M/M, testing
<strong>everyone</strong> may be too expensive and unnecessary.</li>
<li>Instead, testing may be <strong>limited</strong> to applicants
seeking <strong>higher amounts of insurance</strong> to ensure
cost-effectiveness.</li>
<li>Example: In <strong>life insurance</strong>, as mortality rates
improve and underwriting costs rise, insurers have <strong>raised the
insurance amount threshold</strong> for requiring certain medical
tests.</li>
</ul></li>
<li><p><strong>Geographic Variations in Prevalence</strong>:</p>
<ul>
<li>Some conditions, like <strong>HIV infection</strong>, vary by
location.</li>
<li>In such cases, underwriting requirements may depend on <strong>where
the applicant lives</strong>, within <strong>legal
constraints</strong>.</li>
<li>Example: Insurers might require additional testing in regions with
<strong>higher HIV prevalence</strong>.</li>
</ul></li>
<li><p><strong>Age-Based Variations in Prevalence</strong>:</p>
<ul>
<li>Some conditions, like <strong>coronary artery disease</strong>,
become more common <strong>as people age</strong>.</li>
<li>This means underwriting requirements may depend on <strong>both age
and the amount of insurance requested</strong>.</li>
<li>Example: Older applicants may face <strong>stricter health
screenings</strong> for heart disease.</li>
</ul></li>
</ol>
<h3 id="takeaway-8"><strong>Takeaway</strong>:</h3>
<p>Insurers <strong>adjust their underwriting procedures</strong> based
on <strong>prevalence trends</strong> to balance cost-effectiveness and
risk assessment. They may <strong>limit testing</strong> to certain
policy sizes, <strong>adjust requirements based on location</strong>, or
<strong>increase screening for older applicants</strong> based on
disease patterns.</p>
<h3 id="summary-explanation-9"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage highlights a <strong>commonly overlooked factor</strong>
in <strong>protective value studies</strong>: the cost of
<strong>undetected excess mortality/morbidity (M/M)</strong> when not
all applicants undergo underwriting procedures.</p>
<h3 id="key-points-9"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Not Testing Everyone Leads to Undetected
Risk</strong>:</p>
<ul>
<li>To save costs, underwriting procedures are often performed only on
applicants seeking <strong>higher insurance amounts</strong>.</li>
<li>However, this means some applicants with <strong>excess M/M</strong>
(who apply for lower amounts) <strong>go undetected</strong>, leading to
potential <strong>financial losses</strong> for the insurer.</li>
</ul></li>
<li><p><strong>The Trade-off Between Testing Costs &amp; Undetected
M/M</strong>:</p>
<ul>
<li>The decision to <strong>limit testing</strong> is usually based on
<strong>prevalence</strong>—if a condition is rare, testing everyone
isn’t cost-effective.</li>
<li>But <strong>not testing everyone</strong> comes with a cost: some
high-risk applicants will <strong>slip through and be charged standard
rates</strong>, leading to <strong>underpricing and potential
losses</strong>.</li>
</ul></li>
<li><p><strong>Using Business Distribution to Estimate Undetected
Risk</strong>:</p>
<ul>
<li>If insurers know how their policies are distributed <strong>by
coverage amount</strong>, they can estimate <strong>how much undetected
M/M is costing them</strong>.</li>
<li>This helps determine whether a broader or more selective
underwriting approach is more financially beneficial.</li>
</ul></li>
</ol>
<h3 id="takeaway-9"><strong>Takeaway</strong>:</h3>
<p>Limiting underwriting to <strong>higher-value policies</strong> saves
on testing costs but risks <strong>missing high-risk
individuals</strong> who take smaller policies. The <strong>cost of
undetected M/M</strong> should be factored into the overall evaluation
of an underwriting procedure to ensure a <strong>balanced approach
between cost savings and risk management</strong>.</p>
<h3 id="summary-explanation-10"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage provides a <strong>formula</strong> for calculating the
overall <strong>savings</strong> from an underwriting procedure by
accounting for both <strong>tested and untested applicants</strong>.</p>
<h3 id="key-points-10"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Savings Formula</strong>:</p>
<ul>
<li>The <strong>total savings</strong> from an underwriting procedure is
calculated as: [ = ( - ) ]</li>
<li>This means savings depend on both <strong>how common excess
mortality/morbidity (M/M) is (prevalence)</strong> and the difference
between:
<ul>
<li>The <strong>present value (PV) of excess M/M</strong> detected in
<strong>tested</strong> applicants.</li>
<li>The <strong>present value of excess M/M</strong> that goes
undetected in <strong>untested</strong> applicants.</li>
</ul></li>
</ul></li>
<li><p><strong>Factors Affecting Present Values (PV)</strong>:</p>
<ul>
<li><strong>Persistency</strong>:
<ul>
<li>Substandard individuals who are <strong>not tested</strong> tend to
<strong>stay insured longer</strong> (since they may not have better
alternatives), increasing <strong>PV Untested</strong>.</li>
</ul></li>
<li><strong>Interest Rate</strong>:
<ul>
<li>A <strong>higher interest rate</strong> lowers the present value of
excess M/M.</li>
<li>A <strong>lower interest rate</strong> increases it.</li>
</ul></li>
<li><strong>Time Period</strong>:
<ul>
<li>The <strong>longer</strong> the time frame considered, the
<strong>higher</strong> the present value of excess M/M.</li>
</ul></li>
</ul></li>
<li><p><strong>Why This Matters</strong>:</p>
<ul>
<li>If <strong>more high-risk people go undetected</strong>, <strong>PV
Untested increases</strong>, reducing overall savings.</li>
<li>If <strong>testing effectively identifies substandard
risks</strong>, <strong>PV Tested increases</strong>, maximizing
savings.</li>
</ul></li>
</ol>
<h3 id="takeaway-10"><strong>Takeaway</strong>:</h3>
<p>The savings from an underwriting procedure depend on <strong>how well
it detects excess risk</strong> (tested applicants) <strong>versus how
much risk slips through</strong> (untested applicants). Insurers must
balance <strong>prevalence, persistency, interest rates, and time
period</strong> to determine if underwriting procedures are
cost-effective.</p>
<h3 id="summary-explanation-11"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains what should be included in the <strong>cost
calculation</strong> of an underwriting procedure.</p>
<h3 id="key-points-11"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Total Cost Includes More Than Just the Test</strong>:</p>
<ul>
<li>The cost of an underwriting procedure isn’t just the price of
obtaining medical information (e.g., <strong>Attending Physician
Statement (APS)</strong>).</li>
<li>It also includes <strong>administrative and processing
costs</strong>, such as:
<ul>
<li><strong>Mailing fees</strong></li>
<li><strong>Tracking and handling</strong> in the insurer’s system</li>
<li><strong>Data entry and review</strong></li>
</ul></li>
</ul></li>
<li><p><strong>Costs Are Generally Fixed</strong>:</p>
<ul>
<li>These costs <strong>do not vary</strong> based on the <strong>age of
the applicant or the insurance amount</strong>.</li>
<li>Every applicant for whom the procedure is performed incurs
<strong>the same fixed cost</strong>.</li>
</ul></li>
</ol>
<h3 id="takeaway-11"><strong>Takeaway</strong>:</h3>
<p>When evaluating the cost-effectiveness of an underwriting procedure,
insurers must consider <strong>both direct and administrative
costs</strong>. Since these costs are <strong>fixed per
applicant</strong>, insurers need to ensure that the <strong>savings
from detecting excess mortality/morbidity outweigh these costs</strong>
to justify the procedure.</p>
<h3 id="summary-explanation-12"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage introduces the <strong>decision criteria</strong> used
to determine whether an underwriting procedure is financially
justified.</p>
<h3 id="key-points-12"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Core Question</strong>:</p>
<ul>
<li>The fundamental decision is: <strong>“Will I save more than I
spend?”</strong></li>
<li>To answer this, insurers use <strong>two primary
methods</strong>.</li>
</ul></li>
<li><p><strong>Two Decision Criteria</strong>:</p>
<ul>
<li><strong>Break-even Method</strong>:
<ul>
<li>This method determines whether the <strong>savings from the
procedure at least equal its cost</strong>.</li>
<li>If savings <strong>≥ cost</strong>, the procedure is considered
<strong>worth implementing</strong>.</li>
</ul></li>
<li><strong>Return on Investment (ROI) Method</strong>:
<ul>
<li>This method evaluates <strong>how much return</strong> is generated
per dollar spent on the procedure.</li>
<li>ROI helps compare different procedures or investment options
<strong>by measuring profitability</strong>.</li>
</ul></li>
</ul></li>
<li><p><strong>Differences Between the Two</strong>:</p>
<ul>
<li>The <strong>Break-even Method</strong> is a
<strong>pass/fail</strong> test: does the procedure <strong>cover its
cost or not</strong>?</li>
<li>The <strong>ROI Method</strong> provides a <strong>more detailed
financial perspective</strong>, showing how efficient the investment
is.</li>
</ul></li>
</ol>
<h3 id="takeaway-12"><strong>Takeaway</strong>:</h3>
<p>Insurers use <strong>Break-even Analysis</strong> to check if a
procedure is <strong>viable</strong> and <strong>ROI Analysis</strong>
to assess its <strong>profitability</strong>. Understanding both methods
helps in making better underwriting decisions.</p>
<h3 id="summary-explanation-13"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains the <strong>Break-even Method</strong>, a way
to determine if an underwriting procedure is financially justified.</p>
<h3 id="key-points-13"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>Definition of Break-even</strong>:</p>
<ul>
<li>The <strong>break-even (or threshold) level</strong> is the amount
of insurance at which the <strong>savings from the underwriting
procedure exactly equal its cost</strong>.</li>
<li>If an applicant’s insurance amount is <strong>above this
threshold</strong>, the procedure is
<strong>cost-effective</strong>.</li>
</ul></li>
<li><p><strong>Break-even Amount May Not Be Unique</strong>:</p>
<ul>
<li>There can be <strong>multiple break-even points</strong>, meaning
different insurance amounts might yield the same financial result.</li>
<li>The example mentioned (but not provided) would demonstrate
situations where different levels of coverage still result in a
break-even outcome.</li>
</ul></li>
<li><p><strong>Interest Rate Considerations</strong>:</p>
<ul>
<li>The <strong>interest rate</strong> used in break-even calculations
is <strong>arbitrary but fixed</strong>.</li>
<li>However, it should reflect the <strong>insurer’s time-value of
money</strong>, meaning how the company values money now vs. in the
future.</li>
<li>A reasonable choice for this rate is <strong>the one the insurer
uses to establish policy reserves</strong> (the money set aside to pay
future claims).</li>
</ul></li>
</ol>
<h3 id="takeaway-13"><strong>Takeaway</strong>:</h3>
<p>The <strong>Break-even Method</strong> helps determine the minimum
amount of insurance needed for an underwriting procedure to be
<strong>cost-effective</strong>. It relies on <strong>fixed interest
rates</strong> and may have <strong>multiple break-even points</strong>.
The chosen interest rate should align with the insurer’s
<strong>financial strategy</strong>, such as policy reserve
calculations.</p>
<h3 id="summary-explanation-14"><strong>Summary &amp;
Explanation:</strong></h3>
<p>This passage explains the <strong>Return on Investment (ROI)
Method</strong>, another way to assess whether an underwriting procedure
is financially beneficial.</p>
<h3 id="key-points-14"><strong>Key Points:</strong></h3>
<ol type="1">
<li><p><strong>How ROI is Calculated</strong>:</p>
<ul>
<li>The <strong>ROI method</strong> finds the <strong>interest
rate</strong> at which the <strong>savings from the underwriting
procedure exactly equal its cost</strong> for a given amount of
insurance.</li>
<li>This interest rate is referred to as the <strong>ROI</strong>.</li>
</ul></li>
<li><p><strong>Decision Rule</strong>:</p>
<ul>
<li>If the <strong>ROI is greater</strong> than the insurer’s
<strong>time-value of money</strong> (i.e., the rate the insurer uses
for financial decision-making), then the procedure <strong>has
protective value</strong>.</li>
<li>This means the insurer is earning a return on the underwriting
procedure that is higher than their internal financial benchmark, making
the procedure a <strong>worthwhile investment</strong>.</li>
</ul></li>
<li><p><strong>Comparison to the Break-even Method</strong>:</p>
<ul>
<li>If the <strong>ROI equals</strong> the insurer’s time-value of
money, the <strong>ROI method and the Break-even method will yield the
same result</strong>.</li>
<li>The <strong>Break-even method</strong> finds the insurance amount
where savings = cost, while the <strong>ROI method</strong> finds the
interest rate where savings = cost for a given insurance amount.</li>
</ul></li>
</ol>
<h3 id="takeaway-14"><strong>Takeaway</strong>:</h3>
<p>The <strong>ROI Method</strong> evaluates the
<strong>profitability</strong> of an underwriting procedure by
determining whether its return exceeds the insurer’s <strong>financial
benchmark</strong>. If <strong>ROI &gt; time-value of money</strong>,
the procedure is <strong>beneficial</strong>. If <strong>ROI =
time-value of money</strong>, it provides the <strong>same insights as
the Break-even Method</strong>.</p>
    
</body>
</html>